Inivata conducted two prospective, multi-center studies in collaboration with 41 key institutions across the United States. The data, published in JCO Precision Oncology, highlights the potential of Inivata’s first Medicare-reimbursed commercial test to improve delivery of comprehensive tumor genomic profiling.
In this episode of In the Headlines, Jacquelyn Cobb, associate editor of the The Cancer Letter, and Claire Marie Porter, reporter, discuss Claire’s interview with an NCI employee who was fired just days after returning from parental leave.
